Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Inhibition of SRC corrects GM-CSF hypersensitivity that underlies juvenile myelomonocytic leukemia.

Bunda S, Kang MW, Sybingco SS, Weng J, Favre H, Shin DH, Irwin MS, Loh ML, Ohh M.

Cancer Res. 2013 Apr 15;73(8):2540-50. doi: 10.1158/0008-5472.CAN-12-3425. Epub 2013 Feb 11.

2.

CBL linker region and RING finger mutations lead to enhanced granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling via elevated levels of JAK2 and LYN.

Javadi M, Richmond TD, Huang K, Barber DL.

J Biol Chem. 2013 Jul 5;288(27):19459-70. doi: 10.1074/jbc.M113.475087. Epub 2013 May 21.

3.

Juvenile myelomonocytic leukaemia-associated mutation in Cbl promotes resistance to apoptosis via the Lyn-PI3K/AKT pathway.

Bunda S, Qin K, Kommaraju K, Heir P, Ohh M.

Oncogene. 2015 Feb 5;34(6):789-97. doi: 10.1038/onc.2013.596. Epub 2014 Jan 27.

PMID:
24469048
4.

Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34(+) cells of juvenile myelomonocytic leukemia.

Nakazawa Y, Matsuda K, Kurata T, Sueki A, Tanaka M, Sakashita K, Imai C, Wilson MH, Koike K.

J Hematol Oncol. 2016 Mar 16;9:27. doi: 10.1186/s13045-016-0256-3.

5.

[Juvenile myelomonocytic leukemias].

Lachenaud J, Strullu M, Baruchel A, Cavé H.

Bull Cancer. 2014 Mar;101(3):302-13. doi: 10.1684/bdc.2014.1908. Review. French.

PMID:
24691193
6.

CBL mutation-related patterns of phosphorylation and sensitivity to tyrosine kinase inhibitors.

Makishima H, Sugimoto Y, Szpurka H, Clemente MJ, Ng KP, Muramatsu H, O'Keefe C, Saunthararajah Y, Maciejewski JP.

Leukemia. 2012 Jul;26(7):1547-54. doi: 10.1038/leu.2012.7. Epub 2012 Jan 13.

PMID:
22246246
7.

PI3K p110δ uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML.

Goodwin CB, Li XJ, Mali RS, Chan G, Kang M, Liu Z, Vanhaesebroeck B, Neel BG, Loh ML, Lannutti BJ, Kapur R, Chan RJ.

Blood. 2014 May 1;123(18):2838-42. doi: 10.1182/blood-2013-10-535104. Epub 2014 Feb 19.

8.
9.

Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations.

Yoshida N, Doisaki S, Kojima S.

Paediatr Drugs. 2012 Jun 1;14(3):157-63. doi: 10.2165/11631360-000000000-00000. Review.

PMID:
22480363
10.

Quantification of granulocyte-macrophage colony-stimulating factor hypersensitivity in juvenile myelomonocytic leukemia by 3H-thymidine assay.

Tanaka M, Takahashi Y, Xu Y, Yoshida N, Yoshimi A, Villalobos IB, Hama A, Nishio N, Hidaka H, Wang Y, Yagasaki H, Kojima S.

Leuk Res. 2008 Jul;32(7):1036-42. doi: 10.1016/j.leukres.2007.11.016. Epub 2008 Mar 4.

PMID:
18164384
11.

VAV1-Cre mediated hematopoietic deletion of CBL and CBL-B leads to JMML-like aggressive early-neonatal myeloproliferative disease.

An W, Mohapatra BC, Zutshi N, Bielecki TA, Goez BT, Luan H, Iseka F, Mushtaq I, Storck MD, Band V, Band H.

Oncotarget. 2016 Sep 13;7(37):59006-59016. doi: 10.18632/oncotarget.10638.

12.

Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor.

Chan RJ, Leedy MB, Munugalavadla V, Voorhorst CS, Li Y, Yu M, Kapur R.

Blood. 2005 May 1;105(9):3737-42. Epub 2005 Jan 11.

13.

Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia.

Gandre-Babbe S, Paluru P, Aribeana C, Chou ST, Bresolin S, Lu L, Sullivan SK, Tasian SK, Weng J, Favre H, Choi JK, French DL, Loh ML, Weiss MJ.

Blood. 2013 Jun 13;121(24):4925-9. doi: 10.1182/blood-2013-01-478412. Epub 2013 Apr 25.

15.

Dasatinib targets B-lineage cells but does not provide an effective therapy for myeloproliferative disease in c-Cbl RING finger mutant mice.

Duyvestyn JM, Taylor SJ, Dagger SA, Orandle M, Morse HC 3rd, Thien CB, Langdon WY.

PLoS One. 2014 Apr 9;9(4):e94717. doi: 10.1371/journal.pone.0094717. eCollection 2014.

16.

[Juvenile myelomonocytic leukemia (JMML): recent advances in molecular pathogenesis and treatment].

Sakashita K.

Rinsho Ketsueki. 2016 Feb;57(2):137-46. doi: 10.11406/rinketsu.57.137. Review. Japanese.

PMID:
26935631
17.

In vitro expansion of CD34(+)CD38(-) cells under stimulation with hematopoietic growth factors on AGM-S3 cells in juvenile myelomonocytic leukemia.

Sakashita K, Kato I, Daifu T, Saida S, Hiramatsu H, Nishinaka Y, Ebihara Y, Ma F, Matsuda K, Saito S, Hirabayashi K, Kurata T, Uyen LT, Nakazawa Y, Tsuji K, Heike T, Nakahata T, Koike K.

Leukemia. 2015 Mar;29(3):606-14. doi: 10.1038/leu.2014.239. Epub 2014 Aug 8.

PMID:
25102944
18.

Deficiency of β Common Receptor Moderately Attenuates the Progression of Myeloproliferative Neoplasm in NrasG12D/+ Mice.

Zhang J, Ranheim EA, Du J, Liu Y, Wang J, Kong G, Zhang J.

J Biol Chem. 2015 Jul 31;290(31):19093-103. doi: 10.1074/jbc.M115.653154. Epub 2015 Jun 16.

19.

Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia.

Frankel AE, Lilly M, Kreitman R, Hogge D, Beran M, Freedman MH, Emanuel PD, McLain C, Hall P, Tagge E, Berger M, Eaves C.

Blood. 1998 Dec 1;92(11):4279-86.

20.

Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors.

Emanuel PD, Snyder RC, Wiley T, Gopurala B, Castleberry RP.

Blood. 2000 Jan 15;95(2):639-45.

Supplemental Content

Support Center